Human β-cell Precursors Mature Into Functional Insulin-producing Cells in an Immunoisolation Device: Implications for Diabetes Cell Therapies
- 15 April 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (7) , 983-991
Abstract
Background. Islet transplantation is limited by the need for chronic immunosuppression and the paucity of donor tissue. As new sources of human β-cells are developed (e.g., stem cell-derived tissue), transplanting them in a durable device could obviate the need for immunosuppression, while also protecting the patient from any risk of tumorigenicity. Here, we studied (1) the survival and function of encapsulated human β-cells and their progenitors and (2) the engraftment of encapsulated murine β-cells in allo- and autoimmune settings. Methods. Human islets and human fetal pancreatic islet-like cell clusters were encapsulated in polytetrafluorethylene devices (TheraCyte) and transplanted into immunodeficient mice. Graft survival and function was measured by immunohistochemistry, circulating human C-peptide levels, and blood glucose levels. Bioluminescent imaging was used to monitor encapsulated neonatal murine islets. Results. Encapsulated human islet-like cell clusters survived, replicated, and acquired a level of glucose responsive insulin secretion sufficient to ameliorate hyperglycemia in diabetic mice. Bioluminescent imaging of encapsulated murine neonatal islets revealed a dynamic process of cell death followed by regrowth, resulting in robust long-term allograft survival. Further, in the non-obese diabetic (NOD) mouse model of type I diabetes, encapsulated primary β-cells ameliorated diabetes without stimulating a detectable T-cell response. Conclusions. We demonstrate for the first time that human β-cells function is compatible with encapsulation in a durable, immunoprotective device. Moreover, our study suggests that encapsulation of β-cells before terminal differentiation will be a successful approach for new cell-based therapies for diabetes, such as those derived from stem cells.Keywords
This publication has 53 references indexed in Scilit:
- Recovery from diabetes in mice by β cell regenerationJournal of Clinical Investigation, 2007
- Correlation between β cell mass and glycemic control in type 1 diabetic recipients of islet cell graftProceedings of the National Academy of Sciences, 2006
- Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cellsNature Biotechnology, 2006
- Bioluminescent Monitoring of Islet Graft Survival after TransplantationMolecular Therapy, 2004
- Cell‐Based Therapies for Diabetes: Progress towards a Transplantable Human β Cell LineAnnals of the New York Academy of Sciences, 2003
- Presented antigen from damaged pancreatic β cells activates autoreactive T cells in virus-mediated autoimmune diabetesJournal of Clinical Investigation, 2002
- Number and Volume of Islets Transplanted in Immunobarrier DevicesCell Transplantation, 1998
- Immunoisolation of Tumor Cells: Generation of Antitumor Immunity Through Indirect Presentation of AntigenJournal of Immunotherapy, 1997
- Isolation and characterization of a cell line from the epithelial cells of the human fetal pancreasCell Transplantation, 1997
- Implantable biohybrid artificial organsCell Transplantation, 1995